Early markers of cardiovascular risk in chronic kidney disease

References

• Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42(5):1050–1065
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Chavers B, Foley R, et al. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl. 1):S1–S266
   PubMedGoogle Scholar
• Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5):S112–S119
   PubMed Web of Science ®Google Scholar
• Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13(3):745–753
   PubMed Web of Science ®Google Scholar
• Lai S, Coppola B, Dimko M, et al. Vitamin D deficiency, insulin resistance, and ventricular hypertrophy in the early stages of chronic kidney disease. Ren Fail. 2014;36(1):58–64
   PubMed Web of Science ®Google Scholar
• Perna AF, Castaldo P, Ingrosso D, De Santo NG. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin. J Nephrol. 1999;12:230–240
   PubMedGoogle Scholar
• Perna AF, Capasso R, Acanfora F, et al. Toxic effects of hyperhomocysteinemia in chronic renal failure and in uremia: cardiovascular and metabolic consequences. Semin Nephrol. 2006;26(1):20–23
   PubMedGoogle Scholar
• Wierzbicki AS. Homocysteine and cardiovascular disease: A review of the evidence. Diabetes Vasc Dis Res 2007;4(2):143–150
   PubMedGoogle Scholar
• Navaneethan SD, Beddhu S. Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease. Nephrol Dial Transplant. 2009;24:1260–1266
   PubMedGoogle Scholar
• Madero M, Sarnak MJ, Menon V. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009; 53(5):796–803
   PubMed Web of Science ®Google Scholar
• Lai S, Mariotti A, Coppola B, et al. Uricemia and homocysteinemia: nontraditional risk factors in the early stages of chronic kidney disease-preliminary data. Eur Rev Med Pharmacol Sci. 2014;18(7):1010–1017
   PubMedGoogle Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New Engl J Med. 2004;351(13):1296–1305
   PubMed Web of Science ®Google Scholar
• Satyan S, Light RP, Agarwal R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis. 2007;50(6):1009–1019
   PubMed Web of Science ®Google Scholar
• Caliskan Y, Ozkok A, Akagun T, et al. Cardiac biomarkers and noninvasive predictors of atherosclerosis in chronic peritoneal dialysis patients. Kidney Blood Press Res. 2012;35(5):340–348
   PubMed Web of Science ®Google Scholar
• Jafri L, Kashif W, Tai J, et al. B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: selecting the optimal heart failure marker in patients with impaired kidney function. BMC Nephrol. 2013;14:117
   PubMed Web of Science ®Google Scholar
• Scheven L, de Jong PE, Hillege HL, et al.; PREVEND study group. High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. Eur Heart J. 2012;33(18):2272–2281
   PubMed Web of Science ®Google Scholar
• Tagore R, Ling LH, Yang H, et al. Natriuretic peptides in chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(6):1644–1651
   PubMedGoogle Scholar
• Khan IA, Fink J, Nass C, et al. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophyin ambulatory chronic kidney disease patients. Am J Cardiol. 2006;97(10):1530–1534
   PubMed Web of Science ®Google Scholar
• Kocyigit I, Gungor O, Unal A, et al. The effect of strict volume control on cardiac biomarker and arterial stiffness in peritoneal dialysis patients. Clin Nephrol. 2014;81(4):238–246
   PubMedGoogle Scholar
• Stenvinkel P, Carrero JJ, Axelsson J, et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol. 2008;3(2):505–521
   PubMed Web of Science ®Google Scholar
• Williams B, Poulter NR, Brown MJ, et al.; BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): Summary. BMJ. 2004;328(7440):634–640
   PubMed Web of Science ®Google Scholar
• Ho CY, Solomon SD. A clinician's guide to tissue Doppler imaging. Circulation. 2006;113(10):e396–e398
   PubMedGoogle Scholar
• Patel S, Celermajer DS. Assessment of vascular disease using arterial flow mediated dilatation. Pharmacol Rep. 2006;58(Suppl):3–7
   PubMedGoogle Scholar
• Corretti MC, Anderson TJ, Benjamin EJ. Guidelines for the ultrasound assessment of endothelial-dependent flow mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257–265
   PubMed Web of Science ®Google Scholar
• Lang RM, Bierig M, Devereux RB, et al.; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440–1463
   PubMed Web of Science ®Google Scholar
• Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358–367
   PubMed Web of Science ®Google Scholar
• Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55(4):613–618
   PubMed Web of Science ®Google Scholar
• Amann K, Neimeier KA, Schwarz U, et al. Rats with moderate renal failure show capillary deficit in heart but not skeletal muscle. Am J Kidney Dis. 1997;30:382–388
   PubMed Web of Science ®Google Scholar
• Desai AS1, Toto R, Jarolim P, et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis. 2011;58(5):717–728
   PubMed Web of Science ®Google Scholar
• Nanayakkara PW, Kiefte-de Jong JC, Stehouwer CD, et al. Association between global leukocyte DNA methylation, renal function, carotid intima-media thickness and plasma homocysteine in patients with stage 2–4 chronic kidney disease. Nephrol Dial Transplant. 2008;23(8):2586–2592
   PubMedGoogle Scholar
• Yeboah J, Burke GL, Crouse JR, et al. Relationship between brachial flow-mediated dilation and carotid intima-media thickness in an elderly cohort: The Cardiovascular Health Study. Atherosclerosis. 2008;197(2):840–845
   PubMed Web of Science ®Google Scholar
• Wang AY. Clinical utility of natriuretic peptides in dialysis patients. Semin Dial. 2012;25(3):326–333
   PubMedGoogle Scholar
• Horii M1, Matsumoto T, Uemura S, et al. Prognostic value of B-type natriuretic peptide and its amino-terminal proBNP fragment for cardiovascular events with stratification by renal function. J Cardiol. 2013;61(6):410–416
   PubMed Web of Science ®Google Scholar
• Mallamaci F, Zoccali C, Parlongo S, et al. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2002;40:68–75
   PubMed Web of Science ®Google Scholar
• Mallamaci F, Zoccali C, Parlongo S, et al. Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients. Kidney Int. 2002;62:1884–1890
   PubMed Web of Science ®Google Scholar
• Mallamaci F, Tripepi G. Value of troponin T as a screening test for left ventricular hypertrophy in CKD. Am J Kidney Dis. 2013;61(5):689–691
   PubMedGoogle Scholar
• De Filippi C, Wasserman S, Rosanio S, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA. 2003;290:353–359
   PubMed Web of Science ®Google Scholar
• Campuzano R, Moya JL, García-Lledó A, et al. Endothelial dysfunction, intima-media thickness and coronary reserve in relation to risk factors and Framingham score in patients without clinical atherosclerosis. J Hypertens. 2006;24(8):1581–1588
   PubMedGoogle Scholar
• Yan RT, Anderson TJ, Charbonneau F, Title L, Verma S, Lonn E. Relationship between carotid artery intima-media thickness and brachial arteryflow-mediated dilation in middle-aged healthy men. J Am Coll Cardiol. 2005;45(12):1980–1986
   PubMed Web of Science ®Google Scholar